Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Biotech
AstraZeneca pens $630M pact for remaining China rights to CAR-T
The therapy in question, dubbed C-CAR031, is based on AstraZeneca’s own GPC3-targeting CAR-T.
James Waldron
Jan 19, 2026 10:35am
Immunology biotech Agomab, eye-focused SpyGlass share IPO plans
Jan 19, 2026 4:50am
Sponsored
iRegene Secures Historic FDA RMAT for Parkinson’s iPSC Therapy
Jan 19, 2026 8:00am
Fierce Pharma
Exelixis aims to be a top 5 solid tumor drugmaker in the US: CEO
Jan 16, 2026 1:00pm
Sponsored
ExamOne executive details how mobile phlebotomy is reshaping clinical research
Nov 24, 2025 8:00am
Vedanta ‘significantly’ reduces headcount to fund lead program
Jan 16, 2026 11:05am
